Get the Stockscreener App
0.6741
7.89%
0.0493
After Hours:
.68
0.0059
+0.88%
Humacyte Inc stock is traded at $0.6741, with a volume of 3.73M.
It is up +7.89% in the last 24 hours and down -4.87% over the past month.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$0.6248
Open:
$0.6405
24h Volume:
3.73M
Relative Volume:
0.37
Market Cap:
$181.76M
Revenue:
$2.02M
Net Income/Loss:
$-97.59M
P/E Ratio:
-1.173
EPS:
-0.5747
Net Cash Flow:
$-102.38M
1W Performance:
+2.73%
1M Performance:
-4.87%
6M Performance:
-34.55%
1Y Performance:
-73.36%
1-Day Range:
$0.634
$0.6788
1-Week Range:
$0.6211
$0.7099
52-Week Range:
$0.5469
$2.7553
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.6741 | 168.47M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte Inc (HUMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
FDA accepts Humacyte IND for coronary bypass graft study - Investing.com
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting - The Manila Times
Humacyte Plans First Human Study of Bioengineered Vessel in Heart Bypass - Stock Titan
Humacyte Inc (HUMA) Cash Flow - TradingKey
Humacyte Inc (HUMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Humacyte Inc (HUMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Humacyte Market Sentiment - Benzinga España
HUMA|Humacyte Inc|Price:0.625|Chg%:-0.014 - TradingKey
Price to sales forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Humacyte, Inc. (HUMA) Stock Analysis: Exploring a Potential 221% Upside in Biotech Innovation - DirectorsTalk Interviews
Humacyte Inc (HUMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Lobbying Update: $50,000 of HUMACYTE lobbying was just disclosed - Quiver Quantitative
Humacyte, Inc. (HUMA) suffers a larger drop than the general market: Key insights - MSN
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Enterprise value to EBIT forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Investor Notice: Robbins LLP Informs Stockholders of the Class A - GuruFocus
Humacyte, Inc. (HUMA) beats stock market upswing: What investors need to know - MSN
Humacyte appoints two nephrologists as commercial advisors By Investing.com - Investing.com South Africa
Humacyte appoints two nephrologists as commercial advisors - Investing.com
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access - The Manila Times
Form 13D/A HUMACYTE For: 13 July By Investing.com - Investing.com Nigeria
Fresenius to sell 5M Humacyte (HUMA) shares under Rule 10b5-1 plan - Stock Titan
Humacyte Inc (HUMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors - MSN
HUMAHumacyte Inc Options - Finviz
HUMA Should I Buy - Intellectia AI
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securitie - GuruFocus
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Enterprise value to revenue forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte Financial Disclosures & SEC Filings - TradingView
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Humacyte Announces $50 Million Public Offering of Common Stock - Global Legal Chronicle
HUMA stock plunges after-hours on proposed share offering even as dialysis data impresses - MSN
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market - MSN
Enterprise value to revenue forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data - Yahoo Finance
Price to earnings forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Humacyte, Inc. (HUMA) latest stock news and headlines - Yahoo Finance Singapore
Price to book forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Price to sales forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Enterprise value to revenue forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Humacyte, Inc. Actuals & Estimates (NASDAQ:HUMA) - TradingView
Enterprise value to EBITDA forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Enterprise value to EBIT forward of Humacyte, Inc. – BOATS:HUMA - TradingView
HUMA Forecast — Price Target — Prediction for 2027 - TradingView
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
Form 13G Humacyte For: 22 June By Investing.com - Investing.com South Africa
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):